SGLT2 from a Cardiologist point of view

Description

Outline -Direct Effects of SGLTi on the Cardiomyocyte -Diabetes accelerates atherogenesis via vascular damage -Cardiorenal benefits -Major End points in SGLTi Cardiovascular outcome trials in patients with T2DM -Hospitalisation for heart failure -CV death -EMPA-REG Outcome -T2DM choices simpler for cardiologists

Objectives

Presenters

1. Dr. Bernard Gitura
   MMED, FACC, FESC Consultant cardiologist
   Kenyatta National Hospital


2. Dr. Anthony Gikonyo
   Interventional Cardiologist
   Karen Hospital, Nairobi